PTC Therapeutics (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 25,487 shares of the company’s stock on the open market in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $29.86, for a total value of $761,041.82. Following the sale, the chief executive officer now directly owns 135,902 shares of the company’s stock, valued at approximately $4,058,034. PTC Therapeutics, Inc.(NASDAQ:PTCT) shares after opening at $26.51 on last trade day and at the end of the day closed at $25.10. Company price to sales ratio in past twelve months was calculated as 21.76 and price to cash ratio as 5.30. PTC Therapeutics, Inc.(NASDAQ:PTCT) showed a negative weekly performance of -3.72%.
Mar 31, 2014, Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with focus on supportive care products for cancer patients, announced that the Company has completed its previously disclosed three-for-two stock split, effected through a stock dividend. Insys Therapeutics Inc (NASDAQ:INSY) shares fell -3.14% in last trading session and ended the day on $40.11. INSY return on equity ratio is recorded as 165.00% and its return on assets is 67.80%. Insys Therapeutics Inc (NASDAQ:INSY) yearly performance is 446.46%.
On Jan 14, 2014, MediciNova, Inc. (NASDAQ:MNOV), announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis). MediciNova, Inc. (NASDAQ:MNOV) shares moved down -5.41% in last trading session and was closed at $2.10, while trading in range of $2.06 – $2.25. MediciNova, Inc. (NASDAQ:MNOV) year to date (YTD) performance is -1.87%.
On March 31, 2014, Biostar Pharmaceuticals Inc (NASDAQ:BSPM) announced its financial results for the fiscal year ended December 31, 2013. Highlights for the Full Year 2013:Total sales increased to $52.73 million, as compared to $49.32 million for the year ended December 31, 2012.Sales directly to hospitals were up 145% in 2013 to approximately $7.1 million as compared to $2.88 million in 2012.Biostar Pharmaceuticals Inc (NASDAQ:BSPM) weekly performance is 5.61%. On last trading day company shares ended up $2.07. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) distance from 50-day simple moving average (SMA50) is -7.82%. Analysts mean target price for the company is $7.00.